Security
Crescent Biopharma, Inc. Common Stock · CBIO
CBIONASDAQCommon stockCurrentCIK 1253689Updated Oct 28, 2026
Name history
GLYCOMIMETICS INC · through Jun 23, 2025
CBIO price & chart
Loading TradingView…
NASDAQ:CBIO on TradingView ↗About the company
GlycoMimetics is a late clinical-stage biotechnology company that was previously discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach was based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal was to develop transformative therapies for diseases with high unmet medical need. Learn more at www.glycomimetics.com.
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G - filed by BlackRock, Inc. regarding CRESCENT BIOPHARMA, INC.
Other Events
Items 8.01
4 filing
S-8 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 138,269,000Source | 15,698,141Source | 182,758,000Source | 157,433,000Source | 24,418,819Source | 199,130,000Source | 5,992,180Source | 34,204,913Source | 240,293,000Source | 11,091,454Source | 45,316,475Source | 51,810,589Source |
| Property, Plant and Equipment, NetUSD | 782,000Source | — | 876,000Source | 193,000Source | — | 929,000Source | — | — | 846,000Source | — | — | 242,390Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 133,265,000Source | 14,391,664Source | 171,593,000Source | 152,645,000Source | 22,386,052Source | 189,163,000Source | 22,429,000Source | 31,281,460Source | 213,192,000Source | 10,720,178Source | 41,792,830Source | 47,870,619Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 0Source | — | — | 0Source | — | — | 18,000,000Source | — | — | — |
| Assets, CurrentUSD | 134,563,000Source | 15,645,821Source | 179,006,000Source | 154,227,000Source | 23,857,505Source | 195,563,000Source | 5,992,180Source | 33,267,393Source | 236,655,000Source | 11,091,454Source | 43,790,734Source | 50,714,705Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,298,000Source | 1,254,157Source | 7,413,000Source | 1,582,000Source | 1,471,453Source | 6,400,000Source | 377,994Source | 1,985,933Source | 5,463,000Source | 371,276Source | 1,997,904Source | 2,844,086Source |
| Operating Lease, Right-of-Use AssetUSD | 1,564,000Source | — | 1,271,000Source | 1,607,000Source | 424,209Source | 1,372,000Source | — | 598,257Source | 1,469,000Source | — | 767,828Source | 751,174Source |
| Other Assets, NoncurrentUSD | 1,253,000Source | — | 1,498,000Source | 1,300,000Source | — | 1,159,000Source | — | — | 1,216,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 21,628,000Source | 4,321,856Source | 19,503,000Source | 18,179,000Source | 4,356,316Source | 15,283,000Source | 2,616,926Source | 5,294,201Source | 37,281,000Source | 5,777,892Source | 6,902,074Source | 8,880,752Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 14,000Source | 64,484Source | 28,000Source | 14,000Source | 64,484Source | 28,000Source | 64,532Source | 64,451Source | 28,000Source | 64,484Source | 64,394Source | 54,378Source |
| Additional Paid in CapitalUSD | 192,039,000Source | 498,453,419Source | 379,156,000Source | 190,045,000Source | 497,315,304Source | 374,911,000Source | 500,018,828Source | 496,068,140Source | 370,793,000Source | 499,613,448Source | 494,835,219Source | 462,461,251Source |
| Retained Earnings (Accumulated Deficit)USD | -79,412,000Source | -487,141,618Source | -219,929,000Source | -54,805,000Source | -477,317,285Source | -195,092,000Source | -496,708,106Source | -467,221,879Source | -171,809,000Source | -494,364,370Source | -456,485,212Source | -419,585,792Source |
| Stockholders' Equity Attributable to ParentUSD | 116,641,000Source | -1,302,000Source | 163,255,000Source | 139,254,000Source | 20,062,503Source | 183,847,000Source | -30,161,000Source | 28,910,712Source | 203,012,000Source | 5,313,562Source | 38,414,401Source | 42,929,837Source |
| Liabilities and EquityUSD | 138,269,000Source | 15,698,141Source | 182,758,000Source | 157,433,000Source | 24,418,819Source | 199,130,000Source | 5,992,180Source | 34,204,913Source | 240,293,000Source | 11,091,454Source | 45,316,475Source | 51,810,589Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 20,304,000Source | 4,321,856Source | 18,537,000Source | 16,746,000Source | 4,356,316Source | 14,193,000Source | 2,616,926Source | 5,294,201Source | 36,072,000Source | 5,777,892Source | 6,835,230Source | 8,880,752Source |
| Operating Lease, Liability, CurrentUSD | 417,000Source | 262,133Source | 471,000Source | 211,000Source | 448,775Source | 453,000Source | — | 630,827Source | 435,000Source | 66,844Source | 741,558Source | 918,555Source |
| Accounts Payable, CurrentUSD | — | 581,794Source | — | — | 950,763Source | — | 104,671Source | 755,534Source | — | 329,304Source | 868,115Source | 970,191Source |
| Operating Lease, Liability, NoncurrentUSD | 1,324,000Source | — | 966,000Source | 1,433,000Source | — | 1,090,000Source | — | — | 1,209,000Source | — | 66,844Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 8,965,000Source | 3,477,929Source | 7,407,000Source | 7,608,000Source | 2,956,778Source | 4,433,000Source | 2,512,255Source | 3,907,840Source | 16,344,000Source | 5,381,744Source | 5,225,557Source | 6,992,006Source |
| Preferred Stock, Value, Issued | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | -2,343,736Source | — | -37,879,158Source | -36,899,420Source | -46,688,802Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,113,000Source | 1,229,000Source | 13,300,000Source | 4,697,546Source | 3,524,476Source | 3,857,580Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -18,000,000Source | 0Source | 18,000,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | -224,633Source | — | -538,811Source | -102,076Source | -1,137,424Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,937,000Source | -10,851,000Source | -71,532,000Source | -31,098,078Source | -34,879,903Source | -46,457,488Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -8,147,000Source | 0Source | -72,919,000Source | 20,028Source | -21,394Source | -84,191Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 147,000Source | 0Source | 919,000Source | 9,972Source | 21,394Source | 84,191Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -6,945,000Source | -1,486,000Source | 322,984,000Source | 5,398Source | 28,823,508Source | 4,157,408Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -24,029,000Source | -12,337,000Source | 178,533,000Source | -31,072,652Source | -6,077,789Source | -42,384,271Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 133,372,000Source | 0Source | 171,700,000Source | 152,751,000Source | 189,270,000Source | 22,429,000Source | 213,299,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,985,000Source | 1,138,115Source | 3,965,000Source | 5,340,000Source | 4,113,000Source | 1,229,000Source | 13,300,000Source | 4,697,546Source | 3,524,476Source | 3,857,580Source |
| DepreciationUSD | — | — | — | — | — | — | 64,000Source | 0Source | 84,000Source | 35,174Source | 153,301Source | 207,145Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | 1,224,945Source | — | — | — | — | — | 1,224,945Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -46,654Source | -8,627Source | -3,498Source |
| General and Administrative ExpenseUSD | — | — | 5,538,000Source | 4,005,857Source | 8,743,000Source | 8,949,000Source | 7,865,000Source | 3,597,000Source | 25,390,000Source | 18,249,318Source | 19,213,637Source | 19,087,443Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | — | 0Source | 0Source | 0Source | 0Source | 2,000,000Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 0Source | — | 0Source | 1,073,000Source | 0Source | 1,112,000Source | 2,185,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,607,000Source | -9,824,333Source | -24,837,000Source | -21,790,000Source | -23,283,000Source | -15,148,000Source | -153,942,000Source | -37,879,158Source | -36,899,420Source | -46,688,802Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -20,947,000Source | — | -22,689,000Source | -19,004,000Source | -21,262,000Source | -15,148,000Source | -133,446,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | — | 1,409,465Source | — | — | — | — | — | 2,160,220Source | — | — |
| Operating ExpensesUSD | — | — | 25,885,000Source | 11,233,798Source | 28,134,000Source | 21,030,000Source | 25,768,000Source | 14,224,000Source | 163,476,000Source | 40,039,378Source | 39,285,293Source | 47,478,322Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 365,179Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | — | 28,707,011Source | 4,157,408Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 5,000Source | 5,000Source | — | — | — |
| Restructuring Costs and Asset Impairment ChargesUSD | — | — | — | 5,512,594Source | — | — | — | — | — | 7,530,304Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 10,000Source | 75,000Source |
| Operating Lease, Expense | — | — | — | — | — | —Source | — | — | — | — | — | — |
| Other Nonoperating Income (Expense) | — | — | —Source | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 0Source | 0Source | 1,039,000Source | 0Source | 10,844,000Source | — | — | — |
| Operating Income (Loss)USD | — | — | -25,885,000Source | -11,233,798Source | -26,364,000Source | -21,030,000Source | -24,729,000Source | -14,224,000Source | -152,632,000Source | -40,039,378Source | -39,275,293Source | -47,403,322Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -151,942,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | — | 0Source | 0Source | 0Source | 0Source | 2,000,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,607,000Source | -9,824,333Source | -24,837,000Source | -21,790,000Source | -23,283,000Source | -15,148,000Source | -153,942,000Source | -37,879,158Source | -36,899,420Source | -46,688,802Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | — | — | — | — | — | -0.59Source | -0.58Source | -0.89Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | — | — | — | -0.59Source | -0.58Source | -0.89Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | — | — | — | — | — | 64,477,249Source | 63,342,465Source | 52,531,173Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | — | 64,477,249Source | 63,342,465Source | 52,531,173Source |
| Interest Expense (non-operating)USD | — | — | 0Source | — | 0Source | 1,073,000Source | 0Source | 1,112,000Source | 2,185,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 0Source | 2,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 5,538,000Source | 4,005,857Source | 8,743,000Source | 8,949,000Source | 7,865,000Source | 3,597,000Source | 25,390,000Source | 18,249,318Source | 19,213,637Source | 19,087,443Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | 184,520Source | — | — | — | 55,140Source | — | 935,275Source | 2,375,873Source | 714,520Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -20,947,000Source | — | -22,689,000Source | -19,004,000Source | -21,262,000Source | -15,148,000Source | -133,446,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | — | 1,409,465Source | — | — | — | — | — | 2,160,220Source | — | — |
| Operating ExpensesUSD | — | — | 25,885,000Source | 11,233,798Source | 28,134,000Source | 21,030,000Source | 25,768,000Source | 14,224,000Source | 163,476,000Source | 40,039,378Source | 39,285,293Source | 47,478,322Source |
| Research and Development ExpenseUSD | — | — | 20,347,000Source | 1,715,347Source | 19,391,000Source | 12,081,000Source | 17,903,000Source | 10,627,000Source | 138,086,000Source | 14,259,756Source | 20,071,656Source | 28,390,879Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | 10,000Source | 75,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | -3,660,000Source | — | -2,148,000Source | -2,786,000Source | -2,021,000Source | — | -20,496,000Source | — | — | — |
| Other Nonoperating Income (Expense) | — | — | —Source | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Operating Lease, Expense | — | — | — | — | — | —Source | — | — | — | — | — | — |
| Other Operating Income | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-292600
Registration 333-297199
Registration 333-285035
Filing attachments
crescent-sx3xex46formofind.htm · S-3 · 2026-07-01
Exhibit 4.6 CRESCENT BIOPHARMA, INC. INDENTURE Dated as of ___________, 20___ [_________] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. …
Read attachment ↗ex43-cbioxdescriptionofsec.htm · 10-K · 2026-02-26
Exhibit 4.3 DESCRIPTION OF SECURITIES The following is a description of certain terms and provisions of the ordinary shares of the Crescent Biopharma, Inc. (the “Company”). The following summary does not purport to be complete, and is subject to, and qualified in its entirety by, the Memorandum and Articles of Association (the “Articles”), the Company’s Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Shares (the “Series A Certifica…
Read attachment ↗ex44-crescentxformofparasc.htm · 10-K · 2026-02-26
Exhibit 4.4 THIS WARRANT AND THE ORDINARY SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144…
Read attachment ↗tm2518203d1_ex99-1.htm · 8-K · 2025-06-18
EX-99.1 16 tm2518203d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical Data Expected in Second Half of 2026 Shares to Begi…
Read attachment ↗tm2518203d1_ex99-2.htm · 8-K · 2025-06-18
EX-99.2 17 tm2518203d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 CRESCENT BIOPHARMA, INC. CONDENSED BALANCE SHEETS (UNAUDITED) (in thousands except share and per share amounts) March 31, …
Read attachment ↗tm2517051d1_ex99-1.htm · 8-K · 2025-06-06
EX-99.1 2 tm2517051d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals - GlycoMimetics Board of Directors approves 1-for-100 reverse stock split - ROCKVILLE, Md., June 5, 2025 - GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, Inc. (“Crescent”), along with all proposals related to the Me…
Read attachment ↗